Return to homepagePandemic Pact

A Randomized Open-Label Trial of CONvalescent Plasma for Hospitalized Adults With Acute COVID-19 Respiratory Illness (CONCOR-1)

  • Funded by Vancouver Coastal Health Research Institute
  • Total publications:0 publications

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19

  • Funder

    Vancouver Coastal Health Research Institute

  • Principal Investigator

    Dr. Andrew Shih

  • Research Location

    Canada

  • Lead Research Institution

    University of British Columbia Department of Pathology and Laboratory Medicine

  • Research Priority Alignment

    N/A

  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Clinical trials for disease management

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Randomized Controlled Trial

  • Broad Policy Alignment

    Pending

  • Age Group

    Adults (18 and older)

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

Every day, public health officials across Canada report a growing number of people that have fully recovered from COVID-19. These recovered individuals now possess neutralizing antibodies that could be used to increase understanding of COVID-19 and help prevent future fatalities. Recent smaller studies suggest benefit with COVID-19 convalescent plasma (CCP) collected from donors that had contracted and recovered from COVID-19, building on previous evidence that convalescent plasma could provide benefit in other respiratory viruses, such as SARS and MERS. This research project aims to compare standard of care versus the addition of a transfusion of CCP in treating COVID-19 positive patients. Dr. Shih will examine if the use of CCP to treat these patients early in the course of their care could reduce the risk of intubation and improve the rate of survival in adults who are admitted to hospital with COVID-19 respiratory illness. For this study, patients will receive a transfusion of ABO-compatible CCP that has been collected by Canadian Blood Services/Hema-Quebec from donors who have a confirmed prior diagnosis of COVID-19 and have appropriate SARS-CoV-2 antibody and neutralizing antibody titres.